Webinar: Discovery in FCA litigation – Building Bridges to and Avoiding Pitfalls

**Program hosted in (ET) Time Zone**

This webinar will discuss the most important aspects of Discovery in FCA Litigation – including planning for discovery far in advance of unsealing. Challenging privilege logs, selecting the key participants or witnesses for depositions, Touhy requests, and selecting experts.

Discovery in FCA litigation does not begin with unsealing or surviving a motion to dismiss. Planning for discovery begins with the defendant’s responses to the Government’s CIDs (both document production and any interviews conducted), continues through depositions, and must include frontal challenges to privilege logs. Because open discovery after unsealing is often conducted years after the events (at times as much as a decade or more), there is a saying that if you don’t have a document, you won’t have a fact. Thus, documentary evidence and getting clean deposition transcripts to lay foundations for hey documentary evidence to support or respond to the ever-present motion for summary judgment are key to success.

Presented by FBA 2026 Qui Tam Conference sponsor Pietragallo Gordon Alfano Bosick & Raspanti, LLP.

Register Now!

Presenters

Pamela Coyle Brecht, Partner, Pietragallo Gordon Alfano Bosick & Raspanti, LLP
PAMELA COYLE BRECHT is a partner at Pietragallo Gordon Alfano Bosick & Raspanti, LLP. Ms. Brecht serves as Chair of the firm’s national Qui Tam/False Claims Act Practice Group. She is also experienced in white-collar criminal litigation, internal investigations, and complex health care litigation. Ms. Brecht has litigated many of the most complex False Claims Act cases filed in the United States. Her cases have included alleged fraud by a large multi-state Medicaid managed care contractor, FCA violations by three of the largest hospital corporations in the country, and dissecting complex financial relationships among healthcare providers including Stark and Anti-Kickback issues. She has also litigated cases involving hospital fraud, emergency room fraud, medical device allegations, Medicare Part C and Part D fraud, government contractor fraud, laboratory fraud, as well as all types of pharmaceutical fraud. One of the whistleblower matters that Ms. Brecht has worked on was recognized in 2018 by The National Law Journal as one of the “Top 100 Verdicts.” The matter, Lutz v Health Diagnostics Laboratory, ranked as #39 on the list of highest verdicts throughout the nation for that year and came in at #2 for the highest verdicts coming out of Pennsylvania. In addition, Ms. Brecht has served as an expert witness related to alleged conduct involving potential exposure to government enforcement actions.

Marc Stephen Raspanti, Partner, Pietragallo Gordon Alfano Bosick & Raspanti, LLP
MARC STEPHEN RASPANTI is a seasoned trial lawyer with over 41 years of experience focusing on complex, high-stakes matters in Government Enforcement, Compliance, Internal Investigations, Federal and State White Collar Litigation; Federal and State Qui Tam Litigation; Criminal and Civil and Administrative Health Care Fraud Litigation; as well as Complex Commercial Litigation. Chambers USA has ranked Mr. Raspanti in Band 1 for his work in the area of Litigation: White Collar Crime & Government Investigations in Pennsylvania, as well as Band 1 for his work under the False Claims Act: Plaintiff in the USA- Nationwide. Mr. Raspanti is a longstanding Fellow of the American College of Trial Lawyers, an invitation only fellowship of pre-eminent lawyers in the United States and Canada. He served as a former Assistant District Attorney at the Philadelphia District Attorney’s Office where he tried a wide range of criminal cases to verdict. Mr. Raspanti is the founder of the firm’s national Qui Tam & False Claims Act practice group and the firm’s national White Collar Criminal Defense practice group.

Registration

Register Now!

• Live Broadcast | FBA Member: $0
• Live Broadcast | Nonmember: $95
• On-Demand Broadcast | FBA Member: $50
• On-Demand Broadcast | Nonmember: $95